The $100m facility, which will be operated by the company’s subsidiary TOT Biopharm, will produce anti-cancer drug injections.
In addition, the company’s other new facility producing anti-cancer injections, which is ready for pilot run, is expected to begin volume shipments by the end of the year after passing related certifications.
TTY Biopharm chairman RJ Lin was quoted by news.cens.com as saying that, "The company’s pilot-run factory in Chungli, northern Taiwan plans annual capacity of 800,000 injections, and as many as one million by 2013."
The US Food and Drug Administration (FDA) is expected to carry out the new plant’s inspection by the end of this year, as soon as the new factory will start mass production.
The third-stage factory construction of the Suzhou factory is scheduled to be completed in the next four years.
In addition to the production of taxol anti-cancer drug, the company is now stepping into the liposomes anti-drug field, which extends the treatment period and decrease side-effects.